Nanologica develops, manufactures, and sells nanoporous silica particles for life science applications. A proprietary production method enables the company to create world-class products by precisely controlling the shape, size, porosity, and surface properties of silica particles.
Through the two business areas, Chromatography and Drug Development, the company strives to increase the availability of cost-effective drugs and innovative treatments in healthcare, for the benefit of patients around the world.
In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the manufacturing costs for these drugs.
In Drug Development, our inhalation platform is developed to give patients with severe lung diseases access to new or improved treatments.
Silica particles are visible as a fine white powder. The particles are spherical, have a smooth surface, and are fully porous creating a large surface area.
Better and cheaper medicine through porous silica.
We aim to make diabetes drugs and other peptide drugs available to more patients by providing products that can lower the production costs at the manufacturers.
We develop our inhalation platform to give patients with severe lung diseases access to new or improved treatments.
Within the Chromatography business area, Nanologica works to establish a rapidly growing, sustainable and profitable business by providing products for the purification of substances in pharmaceutical production, with a focus on peptides and diabetes drugs. Sales are conducted directly and together with partners on all major markets – India, China, the US and Europe.
In Drug Development, the ambition is to further develop the inhalation area by providing a platform technology based on a unique carrier particle for local delivery of drugs to the lung, via inhalation with a dry powder inhaler. By validating and evaluating chemical, biological, clinical, regulatory, and commercial properties, the most viable drug candidates are selected for further clinical development both in-house and together with partners. The aim is to create improved or completely new opportunities for drug treatment of lung diseases.
Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Nasdaq Stockholm Main Market.